Primary sclerosing cholangitis associated with inflammatory bowel disease

Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disease characterized by inflammation of the intra and extrahepatic bile ducts with progression to cirrhosis. To the present, the etiology of PSC is not known. Although it is possible to establish a correlation with a genetic predisposition, it is an autoimmune disease, associated with ulcerative colitis and Crohn's disease. There is no proven medical treatment that prolongs survival in PSC, being liver transplantation the only curative treatment, with recurrence of 20% of cases within the first five years after transplantation.

• Publication year

  2019

• Venue

  International Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5455/IM.48059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease

  2017cited by this paper
• Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline

  2017cited by this paper
• The Gut-Liver Axis in Primary Sclerosing Cholangitis.

  2016cited by this paper
• Genetic Risk and the Development of Autoimmune Liver Disease

  2015influential reference
• Genetics in PSC: What Do the “Risk Genes” Teach Us?

  2015cited by this paper
• Association Between HLA Haplotypes and Increased Serum Levels of IgG4 in Patients With Primary Sclerosing Cholangitis.

  2015cited by this paper
• Primary sclerosing cholangitis – the Norwegian experience

  2015cited by this paper
• Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis.

  2014cited by this paper
• The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis.

  2014cited by this paper
• Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis.

  2014cited by this paper
• Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis ‐ a pilot study

  2013cited by this paper
• Novel insights into autoimmune liver diseases provided by genome-wide association studies.

  2013influential reference
• Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

  2013cited by this paper
• Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

  2012cited by this paper
• Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis

  2012cited by this paper
• Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

  2012cited by this paper
• Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis.

  2012cited by this paper
• AUTOIMMUNE , CHOLESTATIC AND BILIARY DISEASE Serum Autotaxin Is Increased in Pruritus of Cholestasis , but Not of Other Origin , and Responds To Therapeutic Interventions

  2012cited by this paper
• A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease.

  2012influential reference
• Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease

  2012cited by this paper
• Deciphering the genetic predisposition to primary sclerosing cholangitis.

  2011cited by this paper
• High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

  2007cited by this paper
• Increased prevalence of primary sclerosing cholangitis among first-degree relatives.

  2005cited by this paper
• [Primary sclerosing cholangitis].

  2000influential reference
• Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass.

  1996cited by this paper
• Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.

  1995cited by this paper
• Liver transplantation for sclerosing cholangitis

  1995cited by this paper
• Endoscopic therapy of sclerosing cholangitis

  1995cited by this paper
• End of the beginning

  1990cited by this paper
• Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology.

  1980cited by this paper
• Clinicopathologic features of the syndrome of primary sclerosing cholangitis.

  1980cited by this paper
• Portal bacteraemia in cases of ulcerative colitis submitted to colectomy.

  1969cited by this paper
• Primary sclerosing cholangitis. A study of forty-two cases.

  1966cited by this paper
• Hepatic dysfunction and cirrhosis in chronic ulcerative colitis.

  1948cited by this paper

• Racial Disparities in Inpatient Hospital Outcomes of Primary Sclerosing Cholangitis in United States: Nationwide Analysis

  2024cites this paper
• Magnetic Resonance Imaging of a population-based Cohort of Patients with Long-term Inflammatory Bowel disease. Primary sclerosing cholangitis, bowel damage and inflammation

  2018cites this paper